ArticleFuture oncology (London, England)2025

Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.

Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.